Develops therapies for dermatological and autoimmune diseases, focusing on novel treatments and topical formulations.
MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company focused on advancing treatments for neurologic and neuropsychiatric disorders through two pioneering neuroscience programs.
One of its key innovations is Ketamir-2, an oral ketamine analog with exclusive rights in the U.S., Canada, and Mexico. Ketamir-2 is currently in development to offer rapid antidepressant effects, targeting conditions such as treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.
Additionally, MIRA Pharmaceuticals is exploring the therapeutic potential of MIRA-55, an oral pharmaceutical marijuana formulation aimed at alleviating anxiety and cognitive decline in adult patients, particularly those experiencing early-stage dementia.
Founded in 2020 and headquartered in Miami, Florida, MIRA Pharmaceuticals, Inc., formerly known as MIRA1a Therapeutics, Inc., continues to drive innovation in pharmaceutical research and development, with a strong commitment to addressing significant unmet medical needs in neurology and psychiatry.